Answers drawn only from Abaloparatide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.
What is Abaloparatide?
Abaloparatide, also known as BA058, is a research compound in our hormonal reproductive category. Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP) approved in 2017 for postmenopausal osteoporosis at high fracture risk.
Is Abaloparatide studied in women?
Abaloparatide: of 388 PubMed records, 168 are tagged as including female subjects and 2 carry a sex-analysis tag. We grade this direct female evidence: at least one record carries a sex-analysis tag, so some findings are drawn from women rather than borrowed from mixed or male data. See how we read the evidence.
Has Abaloparatide been studied during pregnancy or breastfeeding?
Contraindicated. Not indicated in women of reproductive potential; no adequate human pregnancy or lactation data. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.
What evidence grade does Abaloparatide have, and why?
Abaloparatide carries evidence grade A. Approved indication with 168 indexed studies that included female subjects.. Grades are derived from the research record, never hand-assigned; see how grades work.
Is there a female-specific dose for Abaloparatide?
No. A female-specific dose for Abaloparatide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.
How is Abaloparatide administered in research?
In the published literature, Abaloparatide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.
What side effects have been reported for Abaloparatide?
Effects reported in the research literature include hypercalciuria, dizziness and orthostatic hypotension, nausea, headache, palpitations, injection-site reaction. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.
What is the CAS number for Abaloparatide?
The CAS registry number for Abaloparatide is 247062-33-5. It is also referred to as BA058, Tymlos, PTHrP(1-34) analog. Use it to confirm identity against a Certificate of Analysis.
How should Abaloparatide be stored and handled?
Abaloparatide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.
Where can I buy Abaloparatide for research?
Abaloparatide is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the Aurevena catalog ↗